{"id":"W4296012068","doi":"10.1016/j.annonc.2022.07.660","title":"532P Analyses of patient-reported outcomes (PROs) with mirvetuximab soravtansine (MIRV) versus standard chemotherapy in the randomized phase III FORWARD I study in ovarian cancer (GOG 3011)","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Ovarian cancer; Chemotherapy; Oncology; Randomized controlled trial; Gynecology; Internal medicine; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00405268,0.0009003454,0.001734793,0.0002563066,0.0002307095,0.0007806635,0.0005983468,0.0008817926,0.003593869],"category_scores_gemma":[0.003605115,0.0003689159,0.005110603,0.0003475237,0.0005270464,0.000901555,0.0005220906,0.001961901,0.0002808004],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005802905,"about_ca_system_score_gemma":0.0006227301,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006549366,"about_ca_topic_score_gemma":0.001248558,"domain_scores_codex":[0.9978722,0.001212858,0.00009809475,0.0003705681,0.0002018188,0.0002443312],"domain_scores_gemma":[0.9978732,0.001153753,0.0005561932,0.0001741219,0.00007364101,0.0001690915],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9178582,0.0008380397,0.02625893,0.0006768742,0.02002832,0.0001000067,0.00005415765,0.002022807,0.005788977,0.0003349813,0.001746733,0.02429203],"study_design_scores_gemma":[0.2858868,0.1962735,0.4163385,0.000351338,0.06685146,0.0006399161,0.000240126,0.01170433,0.01084639,0.00349877,0.007196167,0.0001727496],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9928603,0.002833473,0.0005957593,0.0003483346,0.000167436,0.000109051,0.001959932,0.00003935376,0.001086266],"genre_scores_gemma":[0.9964252,0.0003714178,0.0005146637,0.0002777613,0.00006077168,0.0002443265,0.001223931,0.00002085181,0.0008609711],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00405268,"threshold_uncertainty_score":0.02143288,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1074149896412108,"score_gpt":0.4599319288843317,"score_spread":0.3525169392431209,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}